Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). METHODS: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinicaltrials.gov registration number NCT01386333). Primary outcome measures were safety and tolerability at each dose. Secondary measures explored efficacy across the combined oxytocin vs placebo groups and examined potential dose-related effects. RESULTS: All 3 doses of intranasal oxytocin were safe and well tolerated. CONCLUSIONS: A multicenter trial is warranted to determine the therapeutic efficacy of long-term intranasal oxytocin for behavioral symptoms in FTD. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with FTD, intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Self-citationOxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690 · cited 1×
“Oxytocin administration to healthy adults or patients with autism improves emotional expression processing,(6,7) empathy,(8) and cooperative behavior.(9) A single dose of intranasal oxytocin vs placebo was associated with a transient improvement in social and neuropsychiatric behaviors in patients with FTD.”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Dziobek, I., Rogers, K., Fleck, S., Bahnemann, M., Heekeren, H. R., Wolf, O. T., & Convit, A. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0486-x · Cited by 951 · cited 2×
“Patients completed an exploratory baseline performance measure of empathy, the Multifaceted Empathy Task.20 Vital signs and serum sodium levels were Figure 1 Trial profile Bid 5 twice a day.”
MethodSelf-citationOxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans
Hurlemann, R., Patin, A., Onur, O. A., Cohen, M. X., Baumgartner, T., Metzler, S., Dziobek, I., Gallinat, J., Wagner, M., Maier, W., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5538-09.2010 · Cited by 771
Self-citationOxytocin Increases Retention of Social Cognition in Autism
Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., Anagnostou, E., & Wasserman, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.030 · Cited by 693
Frontal behavioral inventory: diagnostic criteria for frontal lobe dementi
Kertesz, A., Davidson, W., & Fox, H. (1997) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100021053 · Cited by 571 · cited 1×
“For inclusion, participants had to meet the revised international consensus criteria for probable bvFTD(14) or Neary criteria for semantic dementia with concomitant behavioral features, and demonstrate significant deficits in empathy as reported by caregiver responses on the Frontal Behavioral Inventory (FBI).(15) Exc…”
BackgroundSelf-citationIncreased brain and plasma oxytocin after nasal and peripheral administration in rats and mice
Neumann, I. D., Maloumby, R., Beiderbeck, D. I., Lukas, M., & Landgraf, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.003 · Cited by 511 · cited 1×
“In support of this hypothesis, intranasal oxytocin administration to mice increases levels of oxytocin in the amygdala and hippocampus after 30 minutes.(24) This and related work has led to the hypothesis that oxytocin may mediate prosocial behaviors by increasing positive social stimulus processing, reducing anxiety…”
BackgroundDifferent amygdala subregions mediate valence-related and attentional effects of oxytocin in humans
Gamer, M., Zurowski, B., & Büchel, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000985107 · Cited by 487 · cited 1×
“This and related work has led to the hypothesis that oxytocin may mediate prosocial behaviors by increasing positive social stimulus processing, reducing anxiety related to threat cues, and improving the capacity to attend to social cues.(25) Studies examining the neural response to oxytocin administration in FTD are…”
BackgroundStriepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., & Hurlemann, R. (2013) · Scientific Reports · doi:10.1038/srep03440 · Cited by 452
Cited by
Clinical assessment of social cognitive function in neurological disorders
Henry, J. D., von Hippel, W., Molenberghs, P., Lee, T., & Sachdev, P. S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.229 · Cited by 488
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Self-citationDevelopment of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citation
Metadata
- Authors
- Finger, E. C., MacKinley, J., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., Borrie, M., Wells, J., Dziobek, I., Pasternak, S., Mitchell, D. G. V., Rankin, K., Kertesz, A., & Boxer, A.
- Venue
- Neurology
- Published
- 2015-01-13
- Volume
- 84
- Issue
- 2
- Pages
- 174-181
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2004882945
- Cited by
- 100
- References
- 15
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability. https://app.cochat.ai/papers/10.1212/wnl.0000000000001133
- The paper
- Finger, E. C., MacKinley, J., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., Borrie, M., Wells, J., Dziobek, I., Pasternak, S., Mitchell, D. G. V., Rankin, K., Kertesz, A., & Boxer, A. (2015). Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability. Neurology. https://doi.org/10.1212/wnl.0000000000001133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.